Ç÷¿ìº´ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м®, Áúȯ À¯Çüº°, Ä¡·á À¯Çüº°, Ä¡·á¹ýº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B), By Treatment Type (On-demand, Cure), By Therapy, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1771542
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,359,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,764,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,573,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç÷¿ìº´ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è Ç÷¿ìº´ ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.91%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 210¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Ç÷¿ìº´ Ä¡·á¸¦ À§ÇÑ À¯ÀüÀÚ Ä¡·á³ª ´ÜÀÏŬ·ÐÇ×ü°¡ ½ÂÀεǾî, ÆÄÀÌÇÁ¶óÀο¡ ±×·¯ÇÑ È帰¡ º¹¼ö Á¸ÀçÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ç¸Á·üÀÇ ÀúÇÏ¿¡ ÀÇÇØ Ç÷¿ìº´ ȯÀÚÀÇ Æò±Õ ¼ö¸íÀÌ ¿¬ÀåµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿äÀÎÀÔ´Ï´Ù.

Ç÷¿ìº´À» Á¶ÀýÇÏ´Â ½Å±Ô Ä¡·áÁ¦ÀÇ °³¹ß°ú »ó½Ã°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. Á¦Ç° Sevenfact (ÀÀ°í ÀÎÀÚ VIIa(À¯ÀüÀÚ ÀçÁ¶ÇÕ) -jncw)¸¦ ½ÂÀÎÇß½À´Ï´Ù. ¶ÇÇÑ, Ç÷¿ìº´ A Ä¡·áÁ¦ÀÎ BioMarinÀÇ RoctavianÀÌ À¯·´¿¡¼­¸¸ ½ÂÀεǾú°í, CSLÀÇ Hemgenix(etranacogene dezaparvovec-drib)´Â ¹Ì±¹°ú À¯·´ ¸ðµÎ¿¡¼­ ½ÂÀεǾú´Ù´Â Á¡Àº ´Ù¸¥ Áö¿ªÀ¸·ÎÀÇ È®ÀåÀ» À§ÇÑ ±âȸ¸¦ º¸¿©ÁÝ´Ï´Ù. ¹ÙÀÌ¿À ¸¶¸°ÀÇ ·ÏŸºñ¾ÈÀº ÀÌÀü¿¡ °ÅºÎ µÈ ÈÄ ¹Ì±¹ FDA¿¡¼­ °ËÅä ÁßÀ̸ç PDUFA ¸¶°¨ÀÏÀº 2023³â6¿ù30 ÀÏ¿¡ ¼³Á¤µÇ¾ú½À´Ï´Ù.

´ë±â¾÷Àº ½ÅÁ¦Ç° °³¹ß°ú Àü·«Àû Á¦ÈÞ¿¡ ÁÖ·ÂÇÏ¿© Áö¸®Àû Á¸À縦 ³ôÀ̰í ÀÖ½À´Ï´Ù. 2022³â 4¿ù, ³ëº¸ ³ëµð½ºÅ© A/S´Â ij³ª´Ù Ç÷¾× ¼­ºñ½º(Canadian Blood Services)¿Í Á¦ÈÞÇÏ¿© AÇü Ç÷¿ìº´ Ä¡·á¿¡ ½ÃÆÇµÇ´Â ¾à¹°ÀÎ ¿¡½ºÆä·ÏÆ®(Esperoct)¿Í Á¶³ëº£ÀÌÆ®(Zonovate)·Î Á¦Ç° Á¦°øÀ» °­È­Çß½À´Ï´Ù. ¶ÇÇÑ 2023³â 2¿ù, »ç³ëÇÇ(Sanofi)´Â Ç÷¿ìº´ A Ä¡·á¿ë Ç÷¾×ÀÀ°í Á¦VIIIÀÎÀÚ º¸Ãæ¿ä¹ýÀÎ ¾ËÅõºñ¿À(Altuviiio)ÀÇ FDA ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù.

±×·¯³ª Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï ±¹°¡¿¡¼­´Â °æÁõ¿¡¼­ ÁßµîÁõ Áø´ÜÀÌ Áö¿¬µÇ´Â °ÍÀÌ ÁÖ¿ä ÀúÇØ ¿äÀÎÀ̵Ǿú½À´Ï´Ù. ½ÃÀåÀÇ ¶Ç ´Ù¸¥ ÁÖ¿ä °úÁ¦´Â ³ôÀº ºñ¿ë°ú Àå±â µ¥ÀÌÅÍ ºÎÁ·À¸·Î ÀÎÇÑ À¯ÀüÀÚ Ä¡·á Á¢±Ù¼º ¹®Á¦ÀÔ´Ï´Ù.

Ç÷¿ìº´ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ç÷¿ìº´ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Ç÷¿ìº´ ½ÃÀå : Áúȯ À¯ÇüÀÇ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®

Á¦5Àå Ç÷¿ìº´ ½ÃÀå : Ä¡·á À¯ÇüÀÇ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®

Á¦6Àå Ç÷¿ìº´ ½ÃÀå : Ä¡·á¹ý ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®

Á¦7Àå Ç÷¿ìº´ ½ÃÀå : À¯Åë ä³ÎÀÇ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®

Á¦8Àå Ç÷¿ìº´ ½ÃÀå : Áö¿ªÀÇ ÃßÁ¤ ¹× ¿¹Ãø ºÐ¼®

Á¦9Àå °æÀï ±¸µµ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Hemophilia Market Growth & Trends:

The global hemophilia market size is estimated to reach USD 21.07 billion by 2030, registering a CAGR of 6.91% from 2025 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Hemophilia Market Variables, Trends & Scope

Chapter 4. Hemophilia Market: Disease Type Estimates & Trend Analysis

Chapter 5. Hemophilia Market: Treatment Type Estimates & Trend Analysis

Chapter 6. Hemophilia Market: Therapy Estimates & Trend Analysis

Chapter 7. Hemophilia Market: Distribution Channel Estimates & Trend Analysis

Chapter 8. Hemophilia Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â